3D culture modelling: An emerging approach for Translational Cancer Research in Sarcomas
3D culture modelling: An emerging approach for Translational Cancer Research in Sarcomas
Biphasic Hydrogels Integrating Mineralized and Anisotropic Features for Interfacial Tissue Engineering
Biphasic Hydrogels Integrating Mineralized and Anisotropic Features for Interfacial Tissue Engineering
Strontium-releasing mesoporous bioactive glasses with anti-adhesive zwitterionic surface as advanced biomaterials for bone tissue regeneration
Strontium-releasing mesoporous bioactive glasses with anti-adhesive zwitterionic surface as advanced biomaterials for bone tissue regeneration
Combination therapies in the treatment of osteoporosis
Combination therapies in the treatment of osteoporosis
Off-label uses of denosumab in metabolic bone diseases
Bone. 2019 Dec;129:115048. doi:10.1016/j.bone.2019.115048 Polyzos SA, Makras P, Tournis S, Anastasilakis AD
Trends in Prescribing Menopausal Hormone Therapy and Bisphosphonates in Australia and Manitoba, Canada and Adherence to Recommendations
J Womens Health (Larchmt). 2019 Dec 31. doi:10.1089/jwh.2019.7828. Salagame U, Kliewer EV, Demers A, Banks E, Velentzis LS, Goldsbury D, Egger S,Leslie WD, Canfell K.
Spanish National Hip Fracture Registry (RNFC): First-year results and comparison with other registries and prospective multi-centric studies from Spain].
Spanish National Hip Fracture Registry (RNFC): First-year results and comparison with other registries and prospective multi-centric studies from Spain].
Efficacy and safety of denosumab vs.bisphosphonates in postmenopausal women previously treated with oral bisphosphonates.
Efficacy and safety of denosumab vs.bisphosphonates in postmenopausal women previously treated with oral bisphosphonates.
Cholecalciferol and calcifediol for vitamin D supplementation.
Cholecalciferol and calcifediol for vitamin D supplementation.
Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures.
Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures.
